The role of low-molecular–weight heparin in cardiovascular diseases
- 31 October 2002
- journal article
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 45 (2) , 139-156
- https://doi.org/10.1053/pcad.2002.127679
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the essence studyJournal of the American College of Cardiology, 2000
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisThe Lancet, 2000
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary EmbolismNew England Journal of Medicine, 1997
- Low-Molecular-Weight Heparin in the Treatment of Patients with Venous ThromboembolismNew England Journal of Medicine, 1997
- Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)Journal of the American College of Cardiology, 1996
- Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarctionThe American Journal of Cardiology, 1996
- Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable anginaJournal of the American College of Cardiology, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988